Literature DB >> 20974614

Routinely measuring and reporting pneumococcal vaccination among immunosuppressed rheumatology outpatients: the first step in improving quality.

Sonali P Desai1, Alexander Turchin, Lara E Szent-Gyorgyi, Michael Weinblatt, Jonathan Coblyn, Daniel H Solomon, Allen Kachalia.   

Abstract

OBJECTIVE: The Centers for Disease Control (CDC) recommends pneumococcal vaccination for immunocompromised patients. Data suggest that rates of vaccination in this population are not optimal. To support continuous quality improvement efforts, we electronically measured vaccination status among rheumatology outpatients over time.
METHODS: Using data from administrative (billing) and electronic health record sources, we identified rheumatology clinic patients seen between 1 February 2008 and 31 January 2010 and prescribed an immunosuppressive medication. CDC recommendations for pneumococcal vaccination were applied. We calculated the proportion of eligible patients who were up-to-date with pneumococcal vaccination: (i) while on an immunosuppressive medication and (ii) before newly starting an immunosuppressive medication in the last 12 months.
RESULTS: We identified 2763 rheumatology clinic patients on immunosuppressive medications, with 568 initiated in the last 12 months. The mean age was 57 years, 75% were female and 77% were Caucasian. The most frequent disease was RA (50%) and the most common immunosuppressive medication was MTX (59%). Of patients on immunosuppressive medications, 1491/2763 (54%) were up to date with pneumococcal vaccination. Among new initiators of immunosuppressive medications, 258/568 (45%) were vaccinated before starting the immunosuppressive medication. Patients treated by rheumatologists in practice for ≤10 years were more likely to be up to date with pneumococcal vaccination (72%) than those with providers in practice >10 years (52%, P < 0.001).
CONCLUSION: The proportion of patients who are up to date with documented pneumococcal vaccination was suboptimal in our rheumatology practice. The ability to continuously repeat electronic measurement permits us to initiate continuous quality improvement efforts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974614      PMCID: PMC3021950          DOI: 10.1093/rheumatology/keq297

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  31 in total

1.  From a process of care to a measure: the development and testing of a quality indicator.

Authors:  H R Rubin; P Pronovost; G B Diette
Journal:  Int J Qual Health Care       Date:  2001-12       Impact factor: 2.038

2.  Medscape's response to the Institute of Medicine Report: Crossing the quality chasm: a new health system for the 21st century.

Authors:  M Leavitt
Journal:  MedGenMed       Date:  2001-03-05

3.  The quality of health care delivered to adults in the United States.

Authors:  Elizabeth A McGlynn; Steven M Asch; John Adams; Joan Keesey; Jennifer Hicks; Alison DeCristofaro; Eve A Kerr
Journal:  N Engl J Med       Date:  2003-06-26       Impact factor: 91.245

4.  American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care.

Authors:  John A Spertus; Kim A Eagle; Harlan M Krumholz; Kristi R Mitchell; Sharon-Lise T Normand
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

5.  Vaccinate your immunocompromised patients!

Authors:  T Glück
Journal:  Rheumatology (Oxford)       Date:  2006-01       Impact factor: 7.580

6.  Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  Ori Elkayam; Daphna Paran; Dan Caspi; Irena Litinsky; Michael Yaron; Darlene Charboneau; Jeffrey B Rubins
Journal:  Clin Infect Dis       Date:  2001-12-04       Impact factor: 9.079

7.  Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

Authors:  M C Kapetanovic; T Saxne; A Sjöholm; L Truedsson; G Jönsson; P Geborek
Journal:  Rheumatology (Oxford)       Date:  2005-11-15       Impact factor: 7.580

8.  Quality of care for patients with rheumatoid arthritis.

Authors:  C H MacLean; R Louie; B Leake; D F McCaffrey; H E Paulus; R H Brook; P G Shekelle
Journal:  JAMA       Date:  2000 Aug 23-30       Impact factor: 56.272

9.  The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.

Authors:  Ori Elkayam; Dan Caspi; Tatiana Reitblatt; Darlene Charboneau; Jeffrey B Rubins
Journal:  Semin Arthritis Rheum       Date:  2004-02       Impact factor: 5.532

10.  Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.

Authors:  Phillip J Mease; Christopher T Ritchlin; Richard W Martin; Alice B Gottlieb; Scott W Baumgartner; Daniel J Burge; James B Whitmore
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

View more
  7 in total

1.  A Multifaceted Intervention to Improve Influenza, Pneumococcal, and Herpes Zoster Vaccination among Patients with Rheumatoid Arthritis.

Authors:  David W Baker; Tiffany Brown; Ji Young Lee; Amanda Ozanich; David T Liss; Diana S Sandler; Eric M Ruderman
Journal:  J Rheumatol       Date:  2016-04-15       Impact factor: 4.666

2.  The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients.

Authors:  Johanna Nagel; Pierre Geborek; Tore Saxne; Göran Jönsson; Martin Englund; Ingemar F Petersson; Jan-Åke Nilsson; Lennart Truedsson; Meliha C Kapetanovic
Journal:  Arthritis Res Ther       Date:  2015-05-19       Impact factor: 5.156

3.  Improving Influenza and Pneumococcal Vaccination Rates in Ambulatory Specialty Practices.

Authors:  Keyana N Pennant; John J Costa; Anne L Fuhlbrigge; Paul E Sax; Lara E Szent-Gyorgyi; Jonathan Coblyn; Sonali P Desai
Journal:  Open Forum Infect Dis       Date:  2015-10-01       Impact factor: 3.835

4.  Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.

Authors:  Ruth E Costello; Jenny H Humphreys; Kevin L Winthrop; William G Dixon
Journal:  Ann Rheum Dis       Date:  2020-06-26       Impact factor: 19.103

5.  Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.

Authors:  Meliha Crnkic Kapetanovic; Tore Saxne; Lennart Truedsson; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2013-01-04       Impact factor: 5.156

6.  Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.

Authors:  Rieke Alten; Clifton O Bingham; Stanley B Cohen; Jeffrey R Curtis; Sheila Kelly; Dennis Wong; Mark C Genovese
Journal:  BMC Musculoskelet Disord       Date:  2016-05-26       Impact factor: 2.362

7.  Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink.

Authors:  Ruth Costello; Kevin L Winthrop; Stephen R Pye; Benjamin Brown; William G Dixon
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.